Van ECK Associates Corp Increases Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Van ECK Associates Corp boosted its holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 24.4% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 84,834 shares of the biotechnology company's stock after buying an additional 16,658 shares during the period. Van ECK Associates Corp owned approximately 0.09% of Sarepta Therapeutics worth $10,315,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also bought and sold shares of the company. Wellington Management Group LLP boosted its holdings in Sarepta Therapeutics by 32.3% in the 3rd quarter. Wellington Management Group LLP now owns 2,726,613 shares of the biotechnology company's stock valued at $340,527,000 after purchasing an additional 665,087 shares during the period. Erste Asset Management GmbH purchased a new position in shares of Sarepta Therapeutics in the third quarter valued at about $79,425,000. Janus Henderson Group PLC increased its position in shares of Sarepta Therapeutics by 14.2% in the third quarter. Janus Henderson Group PLC now owns 4,358,511 shares of the biotechnology company's stock valued at $544,408,000 after acquiring an additional 543,143 shares during the period. Soros Fund Management LLC purchased a new position in shares of Sarepta Therapeutics in the third quarter valued at about $25,800,000. Finally, Swedbank AB purchased a new position in shares of Sarepta Therapeutics in the fourth quarter valued at about $16,706,000. 86.68% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other news, Director Kathryn Jean Boor sold 1,636 shares of the business's stock in a transaction that occurred on Thursday, December 5th. The shares were sold at an average price of $125.55, for a total transaction of $205,399.80. Following the completion of the transaction, the director now directly owns 5,880 shares of the company's stock, valued at $738,234. The trade was a 21.77 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the business's stock in a transaction that occurred on Thursday, December 12th. The shares were sold at an average price of $124.84, for a total transaction of $1,310,820.00. Following the transaction, the director now directly owns 22,840 shares of the company's stock, valued at $2,851,345.60. The trade was a 31.49 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 7.70% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on SRPT. Robert W. Baird decreased their price objective on shares of Sarepta Therapeutics from $200.00 to $193.00 and set an "outperform" rating on the stock in a research report on Thursday, November 7th. Evercore ISI reduced their price target on shares of Sarepta Therapeutics from $179.00 to $170.00 and set an "outperform" rating on the stock in a research report on Thursday, November 7th. HC Wainwright reiterated a "sell" rating and set a $75.00 price target on shares of Sarepta Therapeutics in a research report on Thursday, February 13th. Deutsche Bank Aktiengesellschaft started coverage on shares of Sarepta Therapeutics in a research report on Tuesday, February 11th. They set a "hold" rating and a $136.00 price target on the stock. Finally, Cantor Fitzgerald upgraded shares of Sarepta Therapeutics from a "neutral" rating to an "overweight" rating and boosted their price target for the company from $152.00 to $167.00 in a research report on Thursday, November 7th. One analyst has rated the stock with a sell rating, three have issued a hold rating, nineteen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $176.77.

Sarepta Therapeutics Stock Up 1.2 %

Shares of NASDAQ SRPT traded up $1.29 during midday trading on Thursday, hitting $108.41. The stock had a trading volume of 836,109 shares, compared to its average volume of 814,482. The business's 50 day moving average is $118.21 and its 200-day moving average is $123.95. The company has a market cap of $10.36 billion, a P/E ratio of 86.73 and a beta of 0.75. Sarepta Therapeutics, Inc. has a 52 week low of $101.15 and a 52 week high of $173.25. The company has a quick ratio of 3.03, a current ratio of 3.84 and a debt-to-equity ratio of 0.93.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.